Malta - englanti - Medicines Authority

g. r. lane health products limited sisson road, gloucester, gl2 0gr, united kingdom - folic acid - tablet - folic acid 0.4 mg - antianemic preparations

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

gr lane health products ltd - folic acid - tablets - 400 microgram - folic acid

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

g.r. lane health products ltd - folic acid - oral tablet - 400microgram

Yhdysvallat - englanti - NLM (National Library of Medicine)

pegasus laboratories, inc. - fluoxetine hydrochloride (unii: i9w7n6b1kj) (fluoxetine - unii:01k63sup8d) - reconcile chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. reconcile chewable tablets are contraindicated for use in dogs with epilepsy or a history of seizures. reconcile chewable tablets should not be given concomitantly with drugs that lower the seizure threshold (e.g., phenothiazines such as acepromazine or chlorpromazine). reconcile chewable tablets should not be given in combination with a monoamine oxidase inhibitor (maoi) [e.g., selegiline hydrochloride (l-deprenyl) or amitraz], or within a minimum of 14 days of discontinuing therapy with an maoi. reconcile chewable tablets are contraindicated in dogs with a known hypersensitivity to fluoxetine hcl or other ssris. because fluoxetine and its major metabolite, norfluoxetine, have long half-lives, a 6-week washout interval should be observed following discontinuation of therapy with reconcile chew-able tablets prior to the administration of any drug that may adversely interact

Yhdysvallat - englanti - NLM (National Library of Medicine)

pegasus laboratories, inc. - fluoxetine hydrochloride (unii: i9w7n6b1kj) (fluoxetine - unii:01k63sup8d) - reconcile chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. reconcile chewable tablets are contraindicated for use in dogs with epilepsy or a history of seizures. reconcile chewable tablets should not be given concomitantly with drugs that lower the seizure threshold (e.g., phenothiazines such as acepromazine or chlorpromazine). reconcile chewable tablets should not be given in combination with a monoamine oxidase inhibitor (maoi) [e.g., selegiline hydrochloride (l-deprenyl) or amitraz], or within a minimum of 14 days of discontinuing therapy with an maoi. reconcile chewable tablets are contraindicated in dogs with a known hypersensitivity to fluoxetine hcl or other ssris. because fluoxetine and its major metabolite, norfluoxetine, have long half-lives, a 6-week washout interval should be observed following discontinuation of therapy with reconcile chew-able tablets prior to the administration of any drug that may adversely interact

Yhdysvallat - englanti - NLM (National Library of Medicine)

pegasus laboratories, inc. - fluoxetine hydrochloride (unii: i9w7n6b1kj) (fluoxetine - unii:01k63sup8d) - reconcile chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. reconcile chewable tablets are contraindicated for use in dogs with epilepsy or a history of seizures. reconcile chewable tablets should not be given concomitantly with drugs that lower the seizure threshold (e.g., phenothiazines such as acepromazine or chlorpromazine). reconcile chewable tablets should not be given in combina-tion with a monoamine oxidase inhibitor (maoi) [e.g., selegiline hydrochloride (l-deprenyl) or amitraz], or within a minimum of 14 days of discontinuing therapy with an maoi. reconcile chewable tablets are contraindicated in dogs with a known hypersensitivity to fluoxetine hcl or other ssris. because fluoxetine and its major metabolite, norfluoxetine, have long half-lives, a 6-week washout interval should be observed following discontinuation of therapy with reconcile chew-able tablets prior to the administration of any drug that may adversely interac

Yhdysvallat - englanti - NLM (National Library of Medicine)

pegasus laboratories, inc. - fluoxetine hydrochloride (unii: i9w7n6b1kj) (fluoxetine - unii:01k63sup8d) - reconcile chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. reconcile chewable tablets are contraindicated for use in dogs with epilepsy or a history of seizures. reconcile chewable tablets should not be given concomitantly with drugs that lower the seizure threshold (e.g., phenothiazines such as acepromazine or chlorpromazine). reconcile chewable tablets should not be given in combination with a monoamine oxidase inhibitor (maoi) [e.g., selegiline hydrochloride (l-deprenyl) or amitraz], or within a minimum of 14 days of discontinuing therapy with an maoi. reconcile chewable tablets are contraindicated in dogs with a known hypersensitivity to fluoxetine hcl or other ssris. because fluoxetine and its major metabolite, norfluoxetine, have long half-lives, a 6-week washout interval should be observed following discontinuation of therapy with reconcile chewable tablets prior to the administration of any drug that may adversely interact

Euroopan unioni - englanti - EMA (European Medicines Agency)

forte healthcare limited - fluoxetine - psychoanaleptics - dogs - as an aid in the treatment of separation-related disorders in dogs manifested by destruction and inappropriate behaviours (vocalisation and inappropriate defecation and / or urination) and only in combination with behavioural-modification techniques.

Yhdysvallat - englanti - NLM (National Library of Medicine)

elanco animal health co - fluoxetine hydrochloride (unii: i9w7n6b1kj) (fluoxetine - unii:01k63sup8d) - fluoxetine hydrochloride 8 mg

Kanada - englanti - Health Canada

pegasus laboratories inc - fluoxetine (fluoxetine hydrochloride) - tablet (chewable) - 8mg - fluoxetine (fluoxetine hydrochloride) 8mg - dogs